These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults. Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224 [TBL] [Abstract][Full Text] [Related]
45. A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands. van Hout BA; Klok RM; Brouwers JR; Postma MJ Clin Ther; 2003 Feb; 25(2):635-46. PubMed ID: 12749518 [TBL] [Abstract][Full Text] [Related]
46. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Simon B; Müller P; Pascu O; Gatz G; Sander P; Huber R; Mascher H Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):791-9. PubMed ID: 12811310 [TBL] [Abstract][Full Text] [Related]
47. Severe esophagitis healed in less than a week with intravenous pantoprazole. Dabney-Smith K; Nam J; Ghazale A; Cai Q J Clin Gastroenterol; 2003 Jan; 36(1):78-9. PubMed ID: 12488715 [No Abstract] [Full Text] [Related]
48. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Parsons ME Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S15-20. PubMed ID: 8930575 [TBL] [Abstract][Full Text] [Related]
49. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. Gillessen A; Beil W; Modlin IM; Gatz G; Hole U J Clin Gastroenterol; 2004 Apr; 38(4):332-40. PubMed ID: 15087692 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease. van Zyl J; van Rensburg C; Vieweg W; Fischer R Digestion; 2004; 70(1):61-9. PubMed ID: 15297779 [TBL] [Abstract][Full Text] [Related]
52. [Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group]. Gallo S; Dibildox M; Moguel A; Di Silvio M; Rodríguez F; Almaguer I; García C Rev Gastroenterol Mex; 1998; 63(1):11-6. PubMed ID: 10068743 [TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Van Rensburg CJ; Honiball PJ; Van Zyl JH; Grundling HD; Eloff FP; Spies SK; Simjee AE; Theron I; Fischer R; Louw JA Aliment Pharmacol Ther; 1999 Aug; 13(8):1023-8. PubMed ID: 10468676 [TBL] [Abstract][Full Text] [Related]
54. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Stupnicki T; Dietrich K; González-Carro P; Straszak A; Terjung A; Thomas KB; Lühmann R; Fischer R Digestion; 2003; 68(4):198-208. PubMed ID: 14707396 [TBL] [Abstract][Full Text] [Related]
55. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Corinaldesi R; Valentini M; Belaïche J; Colin R; Geldof H; Maier C Aliment Pharmacol Ther; 1995 Dec; 9(6):667-71. PubMed ID: 8824655 [TBL] [Abstract][Full Text] [Related]